Therapeutic Areas 

Global domain expertise across an extensive range of therapeutic areas.

Colorized half circle.
therapeutics consultant-min

Best-in-class project teams

Our teams will be assembled to match the therapeutic requirements for your clinical trials. We focus on providing clinical trial solutions that will deliver your studies with responsiveness, flexibility, and a personalized approach. 

Therapeutic Areas of Focus

Our team of experts has decades of experience across a wide variety of therapeutic areas. We work as an extension of your team, bringing you immediate resources who will align with your processes and environment. By partnering with ProPharma, you can leverage our clinical trial execution capabilities with responsiveness, flexibility, and a personalized approach.

 

Obesity & Diabetes

The obesity drug market is rapidly expanding, fueled by the success of innovative treatments. With an increasing number of pharmaceutical companies, particularly smaller and mid-sized firms, aiming to make an impact in this evolving field, the demand for expertly managed clinical trials is more crucial than ever. ProPharma provides specialized services to guide you through the complexities of obesity clinical trials, ensuring your study not only contributes to scientific advancements but also delivers effective treatments to the patients who need them most.

Oncology

ProPharma has a unique combination of experience across the oncology trial space. We have supported clinical studies across a variety of malignancies in both the pediatric and adult patient populations. Our teams have supported radiolabeled studies and understand the unique complexities and regulations involved with delivering this type of study. Our established site relationships and site network allows our teams to support fast study set up and site activation to meet your most challenging goals.

Explore Oncology CRO Solutions

Cardiovascular

ProPharma’s cardiovascular research team has supported clinical trials across a variety of cardiac diseases in both adult and pediatric patient populations. We understand the challenges that come with delivering this type of study for both drug and medical device and diagnostics.

Cell and Gene Therapy

Our Cell and Gene Therapy Center of Excellence helps clients around the world accelerate their novel, advanced therapeutic products to market. We have cell and gene therapy (CAGT) experts that have supported more than 100 different CAGT development programs.

ProPharma’s CAGT consulting team has a combined 25 years of experience delivering unique lifesaving treatments to market in EU, US, and Japanese regulatory environments. Our diverse talent pool supports you across the full development lifecycle to bring products effectively and efficiently to patients.

CNS (Central Nervous System)

With many unmet needs across a myriad of conditions affecting the central nervous system (CNS), every step forward can have a monumental impact on a patient’s health and everyday activities. Armed with experience in a broad range of indications, we can confidently guide you to your neuroscience discovery.

Infectious Diseases and Vaccines

With the fast pace of infectious disease and vaccine trials, our experienced team knows how to ensure the global scale and intellectual property (IP) logistics are in place to allow for accelerated enrollment. We’ve supported a wide variety of global vaccine trials across adult and patient populations, including COVID-19.

MedTech

ProPharma’s MedTech team knows and understands device and diagnostics regulations, and our staff has experience with the regulatory process for clinical trial and product approval in the US and EU. Our clinical team understands the regulatory implications of its actions and decisions, so you can rest assured your clinical study or regulatory submission is in expert hands.

Explore MedTech

Ophthalmology

Our team understands the unique challenges that ophthalmology clinical trials face, such as requiring special imaging vendors and incorporating cell and gene therapy. Our experts know how to design and execute these types of trials efficiently to help accelerate your path to approval.

Pediatrics

Our multidisciplinary clinical team can create a purposeful strategy to navigate the challenges and risk mitigation strategies associated with pediatric studies. With an awareness of the global pediatric landscape, our team can assist in consent/assent, protocol development, and study design. Our cross-functional teams can support the development process including regulatory strategy, protocol development, execution, and regulatory filing.

Rare / Orphan Diseases

In the rare disease space, patients and their families are faced with a lack of available therapies and huge unmet needs. We understand the challenges these patients endure and reducing their burden is our focus. Our cross-functional team of rare disease experts can leverage in-depth experience to navigate the complexity of developing these therapies while having small patient populations and regulatory obstacles at the forefront of the assigned teams.

Respiratory

We have strong experience in many of the unique aspects that define early clinical research with respiratory and inhaled drug products. We help our customers navigate the complex challenges of respiratory clinical trials through our experienced clinical development team.

News & Insights

Rethinking the Role of the Medical Information Contact Center: An Untapped Resource for Medical Writing

May 25, 2026

Rethinking the Role of the Medical Information Contact Center: An Untapped Resou...

Explore how Medical Information contact centers can enhance medical writing by leveraging their expertise and adaptability in response to evolving demands.

Rethinking Biometrics Resourcing in Modern Clinical Trials

May 19, 2026

Rethinking Biometrics Resourcing in Modern Clinical Trials

Explore how the Biometrics Functional Service Provider model transforms clinical trials, enhancing data integrity, speed, and long-term performance in a complex landscape.

The Hidden Value of Medical Information: Strengthening Brand Trust

May 18, 2026

The Hidden Value of Medical Information: Strengthening Brand Trust

Discover how Medical Information strengthens brand trust in the pharmaceutical industry by providing reliable, unbiased, and timely support for patients and healthcare professionals.

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

May 20, 2026

Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed - Pro...

When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...

Case Study Reestablishing FDA Alignment After a CMC Disruption: A Strategic Path to BLA Approval

May 20, 2026

From Clinical Hold to Approval: Overcoming CMC Challenges to Achieve BLA Approva...

A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk. In this case study, learn how we partnered...

Case Study Response to Regulatory Request with Subsequent Full Signal Assessment

May 15, 2026

Response to Regulatory Request with Subsequent Full Signal Assessment - ProPharm...

Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

News & Insights

Rethinking the Role of the Medical Information Contact Center: An Untapped Resource for Medical Writing

May 25, 2026

Rethinking the Role of the Medical Information Contact Center: An Untapped Resou...

Explore how Medical Information contact centers can enhance medical writing by leveraging their expertise and adaptability in response to evolving demands.

Rethinking Biometrics Resourcing in Modern Clinical Trials

May 19, 2026

Rethinking Biometrics Resourcing in Modern Clinical Trials

Explore how the Biometrics Functional Service Provider model transforms clinical trials, enhancing data integrity, speed, and long-term performance in a complex landscape.

The Hidden Value of Medical Information: Strengthening Brand Trust

May 18, 2026

The Hidden Value of Medical Information: Strengthening Brand Trust

Discover how Medical Information strengthens brand trust in the pharmaceutical industry by providing reliable, unbiased, and timely support for patients and healthcare professionals.

Previous Post Arrow Next Post Arrow
ProPharma Appoints Adrian Pencak as Chief Commercial Officer

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

May 20, 2026

Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed - Pro...

When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...

Case Study Reestablishing FDA Alignment After a CMC Disruption: A Strategic Path to BLA Approval

May 20, 2026

From Clinical Hold to Approval: Overcoming CMC Challenges to Achieve BLA Approva...

A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk. In this case study, learn how we partnered...

Case Study Response to Regulatory Request with Subsequent Full Signal Assessment

May 15, 2026

Response to Regulatory Request with Subsequent Full Signal Assessment - ProPharm...

Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...

Previous Resource Arrow Next Resource Arrow
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Previous Webinar Arrow Next Webinar Arrow

Where Personalized Approach Meets Therapeutic Expertise

Meeting the demands of complex therapeutic areas requires expert guidance and a collaborative approach. With global reach and deep industry expertise, we provide personalized solutions and strategic insights, ensuring alignment with your goals every step of the way.